MARKET

AVXL

AVXL

Anavex Life Scie
NASDAQ
0.7194
-0.0206
-2.78%
Pre Market: 0.8348 +0.1154 +16.04% 07:22 11/19 EST
OPEN
0.7385
PREV CLOSE
0.7400
HIGH
0.7800
LOW
0.7150
VOLUME
112
TURNOVER
0
52 WEEK HIGH
5.36
52 WEEK LOW
0.7076
MARKET CAP
66.69M
P/E (TTM)
-4.7454
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at AVXL last week (1109-1113)?
Weekly Report · 3d ago
AVXL Deadline: AVXL Investors Have Opportunity to Lead Anavex Life Sciences Corp. Securities Fraud Lawsuit Filed by The Rosen Law Firm
PR Newswire · 11/11 00:29
What's Next for Anavex Life Sciences Corp. Shareholders After 6.35% Stock Drop? Glancy Prongay Wolke & Rotter LLP Explains Securities Fraud Class Action Lead Plaintiff Deadline
PR Newswire · 11/09 18:00
Weekly Report: what happened at AVXL last week (1102-1106)?
Weekly Report · 11/09 10:01
What Does Anavex Life Sciences Corp.'s 6.35% Stock Drop Mean for Investors? The Law Offices of Howard G. Smith Outlines Securities Fraud Class Action Lead Plaintiff Deadline
PR Newswire · 11/06 19:20
Anavex Deadline: AVXL Investors Have Opportunity to Lead Anavex Life Sciences Corp. Securities Fraud Lawsuit Filed by The Rosen Law Firm
PR Newswire · 11/05 23:15
What Should Anavex Life Sciences Corp. Investors Know After 6.35% Stock Drop? The Law Offices of Frank R. Cruz Outlines Securities Fraud Class Action Lead Plaintiff Deadline
PR Newswire · 11/05 18:50
Anavex Life Sciences Corp. Appoints Terrie Kellmeyer, Ph.D. as Chief Executive Officer and President
NASDAQ · 11/03 15:22
More
About AVXL
Anavex Life Sciences Corp. is a clinical-stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system (CNS) diseases with high unmet need. The Company analyzes genomic data from clinical trials to identify biomarkers, which it uses in the analysis of its clinical trials. Its focus is on developing treatments for Alzheimer’s disease, Parkinson’s disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other CNS disorders. Its pipeline products include ANAVEX 2-73 (blarcamesine) and ANAVEX 3-7. Its other programs include ANAVEX 1-41, ANAVEX 1066 and ANAVEX 1037. ANAVEX 2-73 is being developed as well as an oral once-daily capsule formulation for diseases such as Alzheimer’s disease and Parkinson’s disease, and in an oral liquid once-daily formulation for rare diseases such as Rett syndrome and Fragile X.

Webull offers Anavex Life Sciences Corp stock information, including NASDAQ: AVXL real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AVXL stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading AVXL stock methods without spending real money on the virtual paper trading platform.